R
Rallybio Corporation (RLYB)
8.22
0.00 (0.00%)
Get all premium features to the best stock analysis tool
8.22
0.00 (0.00%)
Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. The company has a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases, as well as collaboration agreement with Johnson & Johnson to provide therapeutic solutions for pregnant individuals at risk of fetal and neonatal alloimmune thrombocytopenia. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut.
| Name | Position |
|---|---|
| Dr. Martin W. MacKay Ph.D. | Co-Founder & Chairman |
| Dr. Stephen Uden M.D., MBBS | Co-Founder, President, CEO & Director |
| Dr. Steven W. Ryder F.A.C.P, M.D. | Chief Medical Officer |
| Mr. Jonathan I. Lieber M.B.A. | CFO & Treasurer |
| Date | Type | Document |
|---|---|---|
| 2026-03-17 | S-4 | d109079ds4.htm |
| 2026-03-16 | 10-K | rlyb-20251231.htm |
| 2026-03-02 | 8-K | d108429d8k.htm |
| 2026-01-29 | 8-K | rlyb-20260126.htm |
| 2026-01-02 | DEF 14A | ny20061662x2_def14a.htm |
| 2025-12-23 | PRE 14A | ny20061662x1_pre14a.htm |
| 2025-11-06 | 10-Q | rlyb-20250930.htm |
| 2025-08-29 | 8-K | d239571d8k.htm |
| 2025-08-07 | 8-K | rlyb-20250807.htm |
| 2025-07-08 | 8-K | rlyb-20250708.htm |